Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

Need For Reform Is Urgent, Health Care Leaders Say
By a wide margin, health care leaders believe that individuals should have a choice of public and private health plans, and strongly support other central components of health reform such as innovative provider payment reform and a national insurance health exchange with strong standard-setting authority. In addition, two-thirds (68%) of opinion leaders feel it is urgent to enact comprehensive health care reform this year, according to the latest Commonwealth Fund/Modern Healthcare Health Care Opinion Leaders Survey.
generic viagra online
SCC Soft Computer Celebrates 30-Year Anniversary With Clients During Annual User Group Meeting
Soft Network Users Group (SNUG) is holding its 17th annual conference, for users of SCC Soft Computer"s (SCC) clinical laboratory software solutions, May 18-21 at the Sheraton Sand Key Resort in Clearwater, Florida. This year"s conference, SNUG 2009- Cultivating Knowledge- a Shared 30-Year Journey of Innovation and Excellence, will include a celebration of SCC Soft Computer"s 30th anniversary with clients and SCC staff members. The conference provides educational opportunities through technical sessions and product demonstrations. Established to promote the free exchange of ideas and suggestions, relating to the applications of SCC Soft Computer"s laboratory software package, SNUG is also a vehicle of communication between users and SCC.
News of the day
Spherix Announces Positive Phase 2 Study Results
Spherix Incorporated (Nasdaq CM: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, announced positive preliminary results from a Phase 2 clinical trial of its novel compound, Naturlose(R) (D-tagatose), in the treatment and management of Type 2 diabetes. The Phase 2 trial is expected to be completed in early 2010.
Nutrition

Emergent BioSolutions Meets With FDA To Review Regulatory Strategy For Recombinant Anthrax Vaccine

Emergent BioSolutions Inc. (NYSE:EBS) announced that it has met with the U.S. Food and Drug Administration (FDA) to review Emergent"s regulatory strategy for the development of its recombinant anthrax (rPA) vaccine. Emergent recently submitted to FDA, among other documents, its rPA Development Plan in response to the Department of Health and Human Services" (HHS) amendment to its request for proposal (RFP) to develop and deliver up to 25 million doses of an rPA vaccine for the Strategic National Stockpile. In amending the RFP, HHS required that all bidders deemed to be in the competitive range submit to FDA a comprehensive plan outlining the regulatory strategy for their rPA vaccine. Emergent completed that submission on May 12, 2009 ahead of the June 15, 2009 submission deadline. "We are extremely pleased with the feedback that we received from FDA regarding our regulatory strategy for the development of our rPA vaccine candidate," stated Daniel Abdun-Nabi, president of Emergent BioSolutions. "This meeting reassured us of the appropriateness of the regulatory strategy that we submitted to FDA and that we can proceed without major modification. As a result of these discussions, Emergent is positioned to advance to the next step in its contract negotiations with HHS for the development and delivery of 25 million doses of an rPA anthrax vaccine to the Strategic National Stockpile." Emergent BioSolutions Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009